Immuno-Oncology Archives - Page 6 of 6 - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

Bristol-Myers Squibb to Pay $1.85 Billion in Record-Breaking Immuno-Oncology Deal with Nektar Therapeutics

February 15, 2018

Leveraging Key Biomarkers to Advance Immuno-Oncology Drug Development and Find the Right Trial Participants

Accelerating Immuno-Oncology Research with the PanCancer IO 360™ Gene Expression Panel, Advanced Data Analysis Service, and Signature Development

December 07, 2017

When is Central Imaging Needed in Clinical Trials?

December 06, 2017

Multiplex IHC Immuno-Oncology Panel – Broadcast 2

November 21, 2017

Multiplex IHC Immuno-Oncology Panel – Broadcast 1

November 21, 2017

German Merck Launches Spinoff Immuno-Oncology Company

FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

Bristol-Myers Squibb’s Opdivo Immunotherapy Receives FDA Approval for Bladder Cancer

February 7, 2017

Operational Excellence in Immuno-Oncology Clinical Trials

January 26, 2017

Tissue Phenomics® at work for immuno-oncology and transplantation medicine

Some Immuno-Oncology Drugs Carry Risk of Rare Heart Damage

November 7, 2016

Bristol-Myers Squibb Acquires Swedish Biotech, Cormorant Pharmaceuticals

Life Science News

AstraZeneca To Explore DNA Damage Drugs As Emerging Oncology Therapy

Elsevier Launches New Open Access Journal For Clinical Trial Professionals

January 11, 2016